The Second PCAC Meeting: 5 More Peptides Coming Before February 2027

While the peptide community is focused on the July 23-24 PCAC meeting reviewing seven peptides, there’s a second meeting already scheduled: before February 2027, the Pharmacy Compounding Advisory Committee will review five additional peptides that were removed from Category 2 in April 2026. These five compounds — including GHK-Cu, Thymosin Alpha-1, and LL-37 — represent some of the most important peptides in the anti-aging, immune support, and wound healing categories.

Getting ahead of this content now positions you to understand the full regulatory picture, not just the immediate headlines.

The Five Peptides Scheduled for Review

Why This Matters

The July 2026 meeting covers the "recovery and performance" peptides (BPC-157, TB-500, MOTS-C). The February 2027 meeting covers the "anti-aging and immune" peptides. Together, these two meetings will determine the regulatory fate of 12 of the most widely used research peptides in the US. The outcomes will shape the entire peptide therapy landscape for years to come.

Peptide-by-Peptide Analysis

GHK-Cu — Strongest Case in Round 2

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) may have the strongest path to a positive recommendation in this group. It is a naturally occurring tripeptide found in human plasma, saliva, and urine. Its concentration declines with age (from ~200 ng/mL in young adults to ~80 ng/mL by age 60), providing a clear rationale for supplementation.

The evidence base includes published human clinical trials for wound healing, cosmetic skin improvement, and hair growth. Multiple new RCTs were initiated in 2025. Its natural origin and extensive safety history give it a compelling profile for the committee.

Thymosin Alpha-1 — The International Precedent

Thymosin Alpha-1 presents a unique case: it’s already approved as a pharmaceutical product (Zadaxin) in 35+ countries for hepatitis B, hepatitis C, and as an immune adjuvant. This international regulatory history provides exactly the kind of human safety and efficacy data the FDA committee looks for.

In the US, it has been used extensively through compounding pharmacies for immune modulation, particularly in cancer support, chronic viral infections, and autoimmune conditions. The fact that it has never received FDA approval in the US despite decades of international use reflects a regulatory gap rather than a safety concern.

LL-37 — Natural Immune Peptide

LL-37 is the only human cathelicidin — an antimicrobial peptide produced naturally by the innate immune system. It’s expressed in skin, gut epithelium, respiratory tract, and immune cells. Research applications include wound healing, antimicrobial defense, and immune modulation.

Its natural origin in the human body is a strong argument for compounding eligibility. The counterargument is that synthetic LL-37 for therapeutic use requires careful quality control, and the FDA may want to see more clinical trial data before recommending compounding.

Thymosin Beta-4 — TB-500’s Parent Compound

Thymosin Beta-4 is the full-length protein from which TB-500 (the active fragment LKKTETQ) is derived. It has been studied in Phase 2 clinical trials for cardiac repair following myocardial infarction and for wound healing. If TB-500 receives a favorable recommendation in July, Thymosin Beta-4 may benefit from that momentum in February.

Melanotan II — The Wild Card

Melanotan II is the most controversial peptide on either agenda. Used primarily for skin tanning and sexual enhancement, it has limited formal clinical data and carries the highest side effect profile of any peptide under review (nausea, facial flushing, darkening of moles). However, its derivative PT-141 (bremelanotide/Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women, which provides at least an indirect legitimization of the melanocortin pathway.

Where to Source These Peptides

Frequently Asked Questions

Related Articles